BNTX Stock Overview
A biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BNTX from our risk checks.
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$102.14 |
| 52 Week High | US$131.49 |
| 52 Week Low | US$76.53 |
| Beta | 0.26 |
| 11 Month Change | -8.46% |
| 3 Month Change | 17.09% |
| 1 Year Change | 4.27% |
| 33 Year Change | -66.49% |
| 5 Year Change | 366.82% |
| Change since IPO | 617.28% |
Recent News & Updates
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Nov 06BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates
Nov 06
Recent updates
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Nov 06BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates
Nov 06BioNTech's Oncology Gamble: High Stakes, Big Potential
Oct 21BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29Shareholder Returns
| BNTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | -6.5% | -1.0% |
| 1Y | 4.3% | 14.6% | 30.3% |
Return vs Industry: BNTX underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: BNTX underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BNTX volatility | |
|---|---|
| BNTX Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BNTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BNTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6,133 | Ugur Sahin | www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
BioNTech SE Fundamentals Summary
| BNTX fundamental statistics | |
|---|---|
| Market cap | US$25.51b |
| Earnings (TTM) | -US$492.10m |
| Revenue (TTM) | US$3.20b |
7.6x
P/S Ratio-49.8x
P/E RatioIs BNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTX income statement (TTM) | |
|---|---|
| Revenue | €3.04b |
| Cost of Revenue | €476.90m |
| Gross Profit | €2.56b |
| Other Expenses | €3.03b |
| Earnings | -€466.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 05, 2025
| Earnings per share (EPS) | -1.95 |
| Gross Margin | 84.31% |
| Net Profit Margin | -15.36% |
| Debt/Equity Ratio | 0% |
How did BNTX perform over the long term?
See historical performance and comparison